| Pre-chemotherapy | Post-chemotherapy | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
BBa | Age range | Sex | WHO (2016) | WCC | Karyotypeb | Sample | Inductionc | Response | Sample | Blast %e | Days since start of Rx | Outcome |
64 | 40–59 | M | AML with inv.(3) | 14.1 | Inv(3) | PB | ADE + GO | Borderline refractory with persistent cytogenetic abnormality | BM | 5% | 33 | Relapsed and died following HSCTf |
121 | 16–39 | F | AML with inv.(3) | 6.5 | Inv(3) | BM | DA + GO | Refractory | BM | 30% | 20 | Transient remission with salvage therapy; then relapsed and died |
205 | 40–59 | F | Therapy-related myeloid neoplasm (t-AML) | 12.6 | Monosomal | PB | DA (90) FLAG-IDA4 | Refractory | BM | 12% | 62d | Relapsed and died following HSCTf |
285 | 60–79 | M | AML with myelodysplasia-related changes | 3.9 | Normal | PB | DA | Refractory | BM | 30% | 32 | Induction failure; died |
349 | 40–59 | M | AML, not otherwise specified | 2.4 | Normal | BM | DA | Refractory | BM | 70% | 38 | Transient remission with salvage therapy; then relapsed and died |
494 | 60–79 | M | AML, not otherwise specified | 30.2 | Monosomal | BM | DA | Refractory | BM | 58% | 32 | Induction failure; died |